Fertility-sparing treatment for endometrial cancer based on molecular type
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You strongly wish to preserve your fertility or keep your uterus
- You have newly diagnosed or recurrent endometrial cancer that is confined to the uterus
- Your tumor has a specific molecular subtype (POLE-mutant, MSI-H, or NSMP) and not the p53-abnormal type
- You must have normal blood counts, liver and kidney function, a good performance status (KPS ≥ 90)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
This trial tests whether using tumor “molecular” results plus standard risk factors can guide the best type and timing of radiation after surgery for early-stage endometrial cancer. It may help you avoid under- or overtreatment by matching radiotherapy to your specific risk.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.